Latus Bio Announces Multiple Oral and Poster Presentations at the Upcoming American Society for Gene and Cell Therapy Annual Meeting
Latus Bio Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced upcoming oral and poster presentations at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting, which is being held from May 13-17th, 2025 in New Orleans, LA. These presentations showcase progress toward advancing Latus’ novel AAV capsid variants - AAV-DB-3 and AAV-Ep+ - to address Huntington’s Disease and CLN2 Batten Disease, respectively.
